Cargando…

Cardiovascular Disease in Diabetes and Chronic Kidney Disease

Chronic kidney disease (CKD) is a common occurrence in patients with diabetes mellitus (DM), occurring in approximately 40% of cases. DM is also an important risk factor for cardiovascular disease (CVD), but CKD is an important mediator of this risk. Multiple CVD outcomes trials have revealed a grea...

Descripción completa

Detalles Bibliográficos
Autores principales: Swamy, Sowmya, Noor, Sahibzadi Mahrukh, Mathew, Roy O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672715/
https://www.ncbi.nlm.nih.gov/pubmed/38002599
http://dx.doi.org/10.3390/jcm12226984
_version_ 1785140456254865408
author Swamy, Sowmya
Noor, Sahibzadi Mahrukh
Mathew, Roy O.
author_facet Swamy, Sowmya
Noor, Sahibzadi Mahrukh
Mathew, Roy O.
author_sort Swamy, Sowmya
collection PubMed
description Chronic kidney disease (CKD) is a common occurrence in patients with diabetes mellitus (DM), occurring in approximately 40% of cases. DM is also an important risk factor for cardiovascular disease (CVD), but CKD is an important mediator of this risk. Multiple CVD outcomes trials have revealed a greater risk for CVD events in patients with diabetes with CKD versus those without. Thus, reducing the risk of CKD in diabetes should result in improved CVD outcomes. To date, of blood pressure (BP) control, glycemic control, and inhibition of the renin-angiotensin system (RASI), glycemic control appears to have the best evidence for preventing CKD development. In established CKD, especially with albuminuria, RASI slows the progression of CKD. More recently, sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide receptor agonists (GLP1RA) have revolutionized the care of patients with diabetes with and without CKD. SGLT2i and GLP1RA have proven to reduce mortality, heart failure (HF) hospitalizations, and worsening CKD in patients with diabetes with and without existing CKD. The future of limiting CVD in diabetes and CKD is promising, and more evidence is forthcoming regarding combinations of evidence-based therapies to further minimize CVD events.
format Online
Article
Text
id pubmed-10672715
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106727152023-11-08 Cardiovascular Disease in Diabetes and Chronic Kidney Disease Swamy, Sowmya Noor, Sahibzadi Mahrukh Mathew, Roy O. J Clin Med Review Chronic kidney disease (CKD) is a common occurrence in patients with diabetes mellitus (DM), occurring in approximately 40% of cases. DM is also an important risk factor for cardiovascular disease (CVD), but CKD is an important mediator of this risk. Multiple CVD outcomes trials have revealed a greater risk for CVD events in patients with diabetes with CKD versus those without. Thus, reducing the risk of CKD in diabetes should result in improved CVD outcomes. To date, of blood pressure (BP) control, glycemic control, and inhibition of the renin-angiotensin system (RASI), glycemic control appears to have the best evidence for preventing CKD development. In established CKD, especially with albuminuria, RASI slows the progression of CKD. More recently, sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide receptor agonists (GLP1RA) have revolutionized the care of patients with diabetes with and without CKD. SGLT2i and GLP1RA have proven to reduce mortality, heart failure (HF) hospitalizations, and worsening CKD in patients with diabetes with and without existing CKD. The future of limiting CVD in diabetes and CKD is promising, and more evidence is forthcoming regarding combinations of evidence-based therapies to further minimize CVD events. MDPI 2023-11-08 /pmc/articles/PMC10672715/ /pubmed/38002599 http://dx.doi.org/10.3390/jcm12226984 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Swamy, Sowmya
Noor, Sahibzadi Mahrukh
Mathew, Roy O.
Cardiovascular Disease in Diabetes and Chronic Kidney Disease
title Cardiovascular Disease in Diabetes and Chronic Kidney Disease
title_full Cardiovascular Disease in Diabetes and Chronic Kidney Disease
title_fullStr Cardiovascular Disease in Diabetes and Chronic Kidney Disease
title_full_unstemmed Cardiovascular Disease in Diabetes and Chronic Kidney Disease
title_short Cardiovascular Disease in Diabetes and Chronic Kidney Disease
title_sort cardiovascular disease in diabetes and chronic kidney disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672715/
https://www.ncbi.nlm.nih.gov/pubmed/38002599
http://dx.doi.org/10.3390/jcm12226984
work_keys_str_mv AT swamysowmya cardiovasculardiseaseindiabetesandchronickidneydisease
AT noorsahibzadimahrukh cardiovasculardiseaseindiabetesandchronickidneydisease
AT mathewroyo cardiovasculardiseaseindiabetesandchronickidneydisease